Hematology

AALL1331 (intermediate- and high-risk relapse)

Study

AALL1331 (low-risk relapse)

Study

AALL1731

Study

Abnormal uterine bleeding

Disease

Acute lymphoblastic leukemia

Disease

Acute myeloid leukemia

Disease

Acute promyelocytic leukemia

Disease

Acute transfusion reactions

Disease

AHA STEROID

Study

Aldolase, increased

Finding

Alemtuzumab

Drug

Allopurinol

Drug

Alternate day vs. daily oral iron in IDA

Study

AMPLIFY (acalabrutinib/venetoclax)

Study

AMPLIFY (acalabrutinib/venetoclax/obinutuzumab)

Study

AMPLIFY (apixaban)

Study

AMPLIFY-EXT (apixaban 2.5 mg)

Study

AMPLIFY-EXT (apixaban 5 mg)

Study

ANAHYDRET

Study

Andexanet alfa

Drug

ANDROMEDA

Study

Anemia of chronic kidney disease

Disease

Antiphospholipid syndrome

Disease

Antiphospholipid syndrome — Investigation

Pathway

APEX

Study

API-CAT

Study

Apixaban

Drug

Aplastic anemia

Disease

AQUILA

Study

ARCADIA (post-hoc analysis)

Study

ARES (aspirin BID vs. aspirin OD)

Study

ARES (aspirin TID vs. aspirin OD)

Study

Artemisinin Combination for Postpartum Malaria

Study

ASC4FIRST

Study

ASCEMBL

Study

ASCEND-D

Study

ASPIRE

Study

Aspirin

Drug

Atrophic gastritis

Disease

ATTRACT

Study

Atypical hemolytic uremic syndrome

Disease

Autoimmune hemolytic anemia

Disease

AVENIR (children)

Study

AVENIR (infants)

Study

AVERT

Study

AVERT (subgroup analysis)

Study

Axatilimab

Drug

AZA-001

Study